Acute Coronary Syndrome, Coronary Artery Disease, Stable Angina
Conditions
Keywords
Prostaglandins, vascular injury
Brief summary
To investigate the biosynthesis of PGD2 during percutaneous transluminal coronary angioplasty (PTCA) procedure.
Detailed description
A) To determine whether biosynthesis of PGD2 is altered in response to vascular injury in humans B) Patients will be grouped base on their aspirin using status. Three groups of no aspirin but an alternative anti-platelet medicine, low dose (81 mg) aspirin, high dose 325 mg aspirin will be enrolled.
Interventions
DRUG325 mg ASA
high dose of aspirin prior to PTCA
DRUGNo ASA
Alternative antiplatelet therapy instead of aspirin
DRUGLow dose ASA
Low dose aspirin (81mg) prior to PTCA
Sponsors
University of Pennsylvania
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Patients with existing CAD admitted for elective PTCA: 1. Treated with any dose of aspirin daily for at least 5 days, with special interest in those treated with 81 mg aspirin daily or 2. Treated with an alternative antiplatelet therapy, such as clopidogrel, due to aspirin hypersensitivity or PMDs preference or 3. No aspirin therapy at all * Patients presenting to the ER with Acute Coronary Syndrome(ACS)who will have a PTCA * Patients with stable angina or positive stress tests scheduled for a cardiac catheterization
Exclusion criteria
* History of unstable diabetes (hgb A1c\>8 or FBS\> 200) * Uncontrolled hypertension (SBP \> 180, DBP \>100) * History of an acute confounding disease as judged on clinical screen that according to the investigator may interfere with interpretation of the study results, or compromise the safety of a potential subject. * Patients who have taken NSAIDS or COX-2 inhibitors other than aspirin, for at least 10 days prior to PTCA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The increment of PGD2 synthesis reflected by an novel biomarker of urinary PGD2 metabolite. | 18-48 hours - which includes 24 hours before the procedure through 18 hours after the procedure for a continuous urine collection. |
Secondary
| Measure | Time frame |
|---|---|
| Whether aspirin could blunt the increment of PGD2 if there is. | 18-48 hours - which includes 24 hours before the procedure through 18 hours after the procedure for a continuous urine collection. |
Outcome results
None listed